title: Prospective randomized comparison of 1-day and 3-day application of topical 0.5% moxifloxacin in eliminating preoperative conjunctival bacteria.
abstract: OBJECTIVE
  Compare the efficacy of a 1-day versus 3-day application of topical 0.5% moxifloxacin in reducing preoperative conjunctival bacteria.
  
  
  METHODS
  Following IRB approval, patients (n = 144) scheduled for ocular surgery between 2004 and 2005 were recruited and randomized to receive topical 0.5% moxifloxacin drops four times a day for either 1 day (n = 63) or 3 days (n = 57) prior to surgery. Conjunctival cultures were obtained at baseline (T0), after application of antibiotic (T1), following povidone-iodine and additional antibiotic applications immediately before surgery (T2), and after surgery (T3). Cultures were inoculated onto blood and chocolate agar plates and in thioglycolate broth, and then incubated at 37 degrees C for 10 days. Bacterial growth were isolated, identified, quantified, and compared.
  
  
  RESULTS
  There were similar (P = 0.8435) rates of patients with positive thioglycolate cultures between the 1-day (79.37%) and 3-day groups (82.46%) at T0. At T1, T2, and T3, the number of eyes with positive cultures were again similar (1 day, 3 days, P value [T1: 34.9%, 35.1%, P = 0.8631; T2: 14.3%, 7%, P = 0.3245; T3: 7.9%, 3.5%, P = 0.5199]). No significant differences were found between the colony-forming units (CFU) of bacteria on solid agar media in 1-day and 3-day groups at any of the time points studied (P values: 0.1-0.8). Coagulase-negative Staphylococcus was the most commonly isolated (73.3% at baseline).
  
  
  CONCLUSIONS
  In patients undergoing intraocular anterior segment surgery, 1-day and 3-day applications of topical 0.5% moxifloxacin appear to have similar efficacy in reducing perioperative conjunctival bacteria.
authors.affiliation: Department of Ophthalmology, School of Medicine, Stanford University, 900 Blake Wilbur Drive, Stanford, CA 94304, USA.
authors.forename: Lingmin
authors.initials: L
authors.lastname: He
authors.forename: Christopher N
authors.initials: CN
authors.lastname: Ta
authors.forename: Nan
authors.initials: N
authors.lastname: Hu
authors.forename: Shamim
authors.initials: S
authors.lastname: Sinnar
authors.forename: Herminia
authors.initials: H
authors.lastname: Miño de Kaspar
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000869:Anterior Eye Segment / Q000601:surgery; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D003228:Conjunctiva / Q000382:microbiology*; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011206:Povidone-Iodine / Q000008:administration & dosage / Q000627:therapeutic use; D011300:Preoperative Care / Q000379:methods*; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method; D013210:Staphylococcus / Q000302:isolation & purification; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D011206:Povidone-Iodine; D000077266:Moxifloxacin